



Data Book

Half Year Ended September 30, 2023

Contents

Financial highlights	
■ Consolidated financial summary	1
■ Consolidated statement of financial position summary	1
■ Consolidated financial indices	1
■ Exchange rates	1
Quarterly consolidated information	
Quarterly consolidated statements of income	2
Quarterly revenue details	3
■ Revenue by business segment	3
■ Revenue by region (Overseas)	3
■ Contribution profit by region	3
■ Revenue of major products	4
Consolidated information	
Consolidated statement of financial position	5
■ Assets	5
■ Equity and liabilities	5
Consolidated statements of cash flows	6

1. Santen Group has adopted International Financial Reporting Standards (IFRS) from the fiscal year ended March 31, 2015, for the purpose of enhancing the international comparability of its financial information.
2. The earnings forecasts and other forward-looking statements contained in this report are based on information currently available to the Company and on certain assumptions deemed to be reasonable by the Company. Actual results may differ from these forecasts due to various factors.
3. Better-than-expected and strong trends in our performance have been observed as a result of strong growth from mainly our overseas business, accelerated streamlining of our pharmaceutical commercial business in the Americas, and continued progress in company wide cost optimizations. In addition, we have completed our impact evaluation from generic products in Japan and as a result, forecasts for our consolidated financial results announced on September 20, 2023, have been revised.

- FY2021: Year ended March 31, 2022
- FY2022: Year ended March 31, 2023
- FY2023: Year ending March 31, 2024

【Contact】
Investor Relations
E-mail: ir@santen.com
Stock Code: 4536